Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jennifer Haig
Cost-Effectiveness of Ranibizumab Versus Aflibercept in the Treatment of Visual Impairment Due to Diabetic Macular Edema: A UK Healthcare Perspective
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
Related publications
Pss34 - Cost-Effectiveness of Intravitreal Aflibercept Versus Ranibizumab in the Treatment of Diabetic Macular Edema in Spain
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Ranibizumab in the Treatment of Patients With Visual Impairment Due to Diabetic Macular Edema
Clinical Ophthalmology
Ophthalmology
Pss25 - Cost-Effectiveness Analysis of Intravitreal Aflibercept Versus Ranibizumab in the Treatment of Diabetic Macular Edema (Dme) Under the Brazilian Public Healthcare System (Sus)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Ophthalmology
Ophthalmology
Intravitreal Ranibizumab for Diabetic Macular Edema With Prompt Versus Deferred Laser Treatment
Ophthalmology
Ophthalmology
Comparison Study of Efficacyinvolving Intravitreal Ranibizumab Versus Standard Laser Mono Therapy in Patients With Visual Impairment Due to Diabetic Macula Edema
IOSR Journal of Dental and Medical Sciences
Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema
JAMA Ophthalmology
Ophthalmology
Extended Injection Intervals After Switching From Ranibizumab to Aflibercept in Macular Edema Due to Central Retinal Vein Occlusion
Journal of Ophthalmology
Ophthalmology
Sub-Macular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema
Case Medical Research
